2025 Biotech Recap & Set Up For 2026

December 11, 2025

47 min episode · 2 min read

Chef Station

Episode

47 min

Read time

2 min

AI-Generated Summary

Published Mar 14, 2026

Key Takeaways

✓FDA Advisory Committee Reduction: The FDA issued nearly zero advisory committee meetings for PDUFA reviews in 2025, a sharp departure from prior years. Traders who previously built strategies around AdCom volatility need to adjust—two January 2026 PDUFAs (TVTX on January 13, AQST on January 31) have both been confirmed AdCom-free, reducing pre-approval uncertainty and supporting longer holding periods.
✓CRL Resubmission Trading Framework: Complete response letters increasingly represent solvable process issues rather than safety or efficacy failures. Milestone Pharma's December 13 PDUFA exemplifies this—its prior CRL stemmed from nitrosamine guidance updates, not trial data. Tracking the specific CRL reason, subsequent FDA feedback, and analyst rerate commitments from firms like Cowen helps identify higher-probability approval setups.
✓Institutional 13F Tracking as Entry Signal: Monitoring 13F filings from healthcare-specialist funds—specifically Adar Capital Management, Affinity Advisors, RA Capital, and Opaleye—provides actionable entry signals. Adar's early position in Abavex at $8–9 preceded a run to $120. Current large Adar positions in Quince Therapeutics (QNCX) and Ovid Therapeutics signal anticipated positive phase three data in early 2026.
✓Single Phase 3 Study NDA Pathway: The FDA now accepts single phase three studies for NDA submissions in select cases via Type C meetings, previously requiring two studies demonstrating statistical significance. Identifying companies that have secured this pathway—confirmed through meeting disclosures—materially reduces development risk and timeline, making them more attractive acquisition targets for larger pharmaceutical companies seeking pipeline assets.
✓GLP-1 Maintenance as Emerging Investment Theme: Fractal Health (ticker: GUTS) targets patients who plateau or discontinue GLP-1 weight-loss drugs using its Revita procedure. Six-month REMAIN study data showing post-discontinuation weight maintenance arrives in January 2026. Seven new institutional funds entered positions in Q3 2025 with zero exits—a consensus signal worth tracking ahead of the readout and subsequent JPMorgan conference presentations.

What It Covers

Biotech trading veteran "Chef" and BioPharm Catalyst's John Galliano review 2025 biotech market conditions—including increased FDA transparency, reduced advisory committee requirements, and rising institutional investment—then preview 14 specific small-cap catalyst plays with near-term data readouts heading into JPMorgan 2026.

Key Questions Answered

•FDA Advisory Committee Reduction: The FDA issued nearly zero advisory committee meetings for PDUFA reviews in 2025, a sharp departure from prior years. Traders who previously built strategies around AdCom volatility need to adjust—two January 2026 PDUFAs (TVTX on January 13, AQST on January 31) have both been confirmed AdCom-free, reducing pre-approval uncertainty and supporting longer holding periods.
•CRL Resubmission Trading Framework: Complete response letters increasingly represent solvable process issues rather than safety or efficacy failures. Milestone Pharma's December 13 PDUFA exemplifies this—its prior CRL stemmed from nitrosamine guidance updates, not trial data. Tracking the specific CRL reason, subsequent FDA feedback, and analyst rerate commitments from firms like Cowen helps identify higher-probability approval setups.
•Institutional 13F Tracking as Entry Signal: Monitoring 13F filings from healthcare-specialist funds—specifically Adar Capital Management, Affinity Advisors, RA Capital, and Opaleye—provides actionable entry signals. Adar's early position in Abavex at $8–9 preceded a run to $120. Current large Adar positions in Quince Therapeutics (QNCX) and Ovid Therapeutics signal anticipated positive phase three data in early 2026.
•Single Phase 3 Study NDA Pathway: The FDA now accepts single phase three studies for NDA submissions in select cases via Type C meetings, previously requiring two studies demonstrating statistical significance. Identifying companies that have secured this pathway—confirmed through meeting disclosures—materially reduces development risk and timeline, making them more attractive acquisition targets for larger pharmaceutical companies seeking pipeline assets.
•GLP-1 Maintenance as Emerging Investment Theme: Fractal Health (ticker: GUTS) targets patients who plateau or discontinue GLP-1 weight-loss drugs using its Revita procedure. Six-month REMAIN study data showing post-discontinuation weight maintenance arrives in January 2026. Seven new institutional funds entered positions in Q3 2025 with zero exits—a consensus signal worth tracking ahead of the readout and subsequent JPMorgan conference presentations.

Notable Moment

Chef reveals that TVTX's advisory committee meeting—typically scheduled six weeks before a PDUFA date—never materialized despite a January 13 approval deadline. Rather than signaling trouble, the pattern across 2025 suggests the FDA is bypassing AdComs entirely, fundamentally changing how traders should structure their pre-approval positioning timelines.

Know someone who'd find this useful?